Want to see JP:4574 full AI Analyst Report?
Total Valuation
Taiko Pharmaceutical Co., Ltd. has a market cap or net worth of ¥12.87B. The enterprise value is ¥11.23K.
Market Cap¥12.87B
Enterprise Value¥11.23K
Share Statistics
Taiko Pharmaceutical Co., Ltd. has 50,636,900 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding50,636,900
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Taiko Pharmaceutical Co., Ltd.’s return on equity (ROE) is 0.11 and return on invested capital (ROIC) is 4.19%.
Return on Equity (ROE)0.11
Return on Assets (ROA)0.08
Return on Invested Capital (ROIC)4.19%
Return on Capital Employed (ROCE)0.05
Revenue Per Employee29.08M
Profits Per Employee4.20M
Employee Count220
Asset Turnover0.52
Inventory Turnover1.80
Valuation Ratios
The current PE Ratio of Taiko Pharmaceutical Co., Ltd. is 18.8. Taiko Pharmaceutical Co., Ltd.’s PEG ratio is 6.05.
PE Ratio18.8
PS Ratio2.34
PB Ratio1.76
Price to Fair Value1.76
Price to FCF28.62
Price to Operating Cash Flow0.00
PEG Ratio6.05
Income Statement
In the last 12 months, Taiko Pharmaceutical Co., Ltd. had revenue of 6.40B and earned 923.00M in profits. Earnings per share was 18.37.
Revenue6.40B
Gross Profit3.48B
Operating Income459.00M
Pretax Income958.00M
Net Income923.00M
EBITDA724.00M
Earnings Per Share (EPS)18.37
Cash Flow
In the last 12 months, operating cash flow was 0.00 and capital expenditures 0.00, giving a free cash flow of 0.00 billion.
Operating Cash Flow0.00
Free Cash Flow0.00
Free Cash Flow per Share0.00
Dividends & Yields
Taiko Pharmaceutical Co., Ltd. pays an annual dividend of ¥3.5, resulting in a dividend yield of 1.28%
Dividend Per Share¥3.5
Dividend Yield1.28%
Payout Ratio24.10%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.66
52-Week Price Change-14.90%
50-Day Moving Average260.26
200-Day Moving Average280.06
Relative Strength Index (RSI)48.54
Average Volume (3m)104.25K
Important Dates
Taiko Pharmaceutical Co., Ltd. upcoming earnings date is Nov 6, 2026, TBA (Confirmed).
Last Earnings DateAug 13, 2026
Next Earnings DateNov 6, 2026
Ex-Dividend Date―
Financial Position
Taiko Pharmaceutical Co., Ltd. as a current ratio of 3.36, with Debt / Equity ratio of 2.04%
Current Ratio3.36
Quick Ratio2.72
Debt to Market Cap0.05
Net Debt to EBITDA-4.75
Interest Coverage Ratio91.80
Taxes
In the past 12 months, Taiko Pharmaceutical Co., Ltd. has paid 34.00M in taxes.
Income Tax34.00M
Effective Tax Rate0.04
Enterprise Valuation
Taiko Pharmaceutical Co., Ltd. EV to EBITDA ratio is 15.93, with an EV/FCF ratio of 22.05.
EV to Sales1.80
EV to EBITDA15.93
EV to Free Cash Flow22.05
EV to Operating Cash Flow14.17
Balance Sheet
Taiko Pharmaceutical Co., Ltd. has ¥3.83B in cash and marketable securities with ¥479.00M in debt, giving a net cash position of ¥3.35B billion.
Cash & Marketable Securities¥3.83B
Total Debt¥479.00M
Net Cash¥3.35B
Net Cash Per Share¥66.22
Tangible Book Value Per Share¥168.96
Margins
Gross margin is 52.85%, with operating margin of 7.18%, and net profit margin of 14.43%.
Gross Margin52.85%
Operating Margin7.18%
Pretax Margin14.98%
Net Profit Margin14.43%
EBITDA Margin11.32%
EBIT Margin7.18%
Analyst Forecast
The average price target for Taiko Pharmaceutical Co., Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast13.30%
EPS Growth Forecast66.38%